Investor Relations

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. 

Date Title and Summary
Toggle Summary MedImmune and Juno Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
GAITHERSBURG, Md. and SEATTLE, April 23, 2015 (GLOBE NEWSWIRE) -- MedImmune, the global biologics research and development arm of AstraZeneca, and Juno Therapeutics, Inc. , a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,
Toggle Summary Leading Cancer Research Centers Team up to Launch Biotech Startup Focused on Cancer Immunotherapy
Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute join together to launch Juno Therapeutics Inc. Company founded with $120M initial investment, among largest fully committed Series A for a biotech startup in
Toggle Summary Juno’s Investigational CAR T Cell Product Candidates JCAR018 and JTCR016 Demonstrate Encouraging Clinical Responses in Patients with B-Cell and Mesothelioma Cancers
– Promising complete remission and complete molecular remission rates for CD22 CAR T cell product candidate in pediatric and young adult ALL – – Early signs of activity in the WT-1 TCR program in mesothelioma – – Data Presented at American Association for Cancer Research (AACR) Annual Meeting 2016
Toggle Summary Juno’s Investigational CAR T Cell Product Candidates JCAR015 and JCAR014 Demonstrate Encouraging Clinical Responses in Patients with B-cell Cancers
-- Continued positive results in relapsed or refractory acute lymphoblastic leukemia -- -- Analyst and Investor Event with Webcast on Monday, December 7 at 8:30 p.m. Eastern Time -- SEATTLE --(BUSINESS WIRE)--Dec. 7, 2015-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused


View all events

Copyright Nasdaq. Minimum 15 minutes delayed.